In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Catch a Falling Star

Executive Summary

Serono's €104.7 cash offer for France's Genset came just in time for the cash-strapped genomics play, once the star of French biotech. Critics claim Serono's 195% premium for an almost-bankrupt company is nothing short of crazy, but Serono reckons it's spotted an unexploited asset.

You may also be interested in...



Deal Early, Less Often: ZymoGenetics' Broad Deal with Serono

The broad research, development and commercialization alliance inked in September between ZymoGenetics Inc. and Serono SA stands out not only for its size and scope--an unlimited number of proteins and up-front equity purchases and license fees totalling $81.25 million--but also because each partner is a biotech company, and the research chores will be shared from the outset.

Endocube SAS

Endocube, a French firm set up in 2001, aims to get at the genetic roots of inflammatory processes by investigating previously undescribed enzymes located on the surface of cuboidal cells--endothelial cells that have turned cube-like as a result of chronic inflammation.

NicOx: Challenging the Cox-2s?

Recent concerns over the cardiovascular risk profile of Cox-2 inhibitors strengthen the case for pain compound AZD 3582, a new formulation of naproxen in Phase II trials at AstraZeneca. For the compound's originator, NicOx, forthcoming trial results will be critical in validating the firm's founding concept: grafting a nitric oxide molecule onto existing generic drugs.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV004603

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel